Advertisement
News
Advertisement

Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration

Mon, 07/12/2010 - 7:35am
Bio-Medicine.Org

SAN DIEGO, PARSIPPANY, N.J. and INDIANAPOLIS, July 12 /PRNewswire/ -- Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of platelet function testing.

Several factors, including a patient's genetic make-up, diabetic status, age, weight and the use of certain other medications metabolized through the cytochrome P450 pathway in the body may influence patient response to antiplatelet medicines.  Therefore, it is important that physicians understand their options to determine if their use of a specific antiplatelet medicine is having its intended effect.

Antiplatelet medicines help prevent blood platelets from sticking or clumping together, reducing the likelihood that arteries will be blocked by a clot, leading to a heart attack.

The focus of the collaboration is to educate healthcare professionals about the availability and reliability of a rapid and easy-to-use platelet function test, and to stress the importance of assessing each patient's platelet response to antiplatelet medications.

"By working closely with Daiichi Sankyo and Lilly, we hope to offer greater understanding of platelet function testing as a means to help physicians assess patients' platelet response to antiplatelet therapy," said Timothy I. Still, President and CEO of Accumetrics.    

"We believe physicians will want to know the specific effect of a patient's antiplatelet therapy and whether additional measures may be needed," said

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading